ADOCIA/S (OTCMKTS:ADOCY) and Standard Diversified Inc Class A (NYSEAMERICAN) (NYSE:SDI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
This is a summary of current recommendations for ADOCIA/S and Standard Diversified Inc Class A (NYSEAMERICAN), as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Standard Diversified Inc Class A (NYSEAMERICAN)||0||0||0||0||N/A|
Valuation & Earnings
This table compares ADOCIA/S and Standard Diversified Inc Class A (NYSEAMERICAN)’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ADOCIA/S||$21.99 million||4.30||-$9.66 million||N/A||N/A|
|Standard Diversified Inc Class A (NYSEAMERICAN)||$285.80 million||0.78||$10.37 million||N/A||N/A|
Standard Diversified Inc Class A (NYSEAMERICAN) has higher revenue and earnings than ADOCIA/S.
This table compares ADOCIA/S and Standard Diversified Inc Class A (NYSEAMERICAN)’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Standard Diversified Inc Class A (NYSEAMERICAN)||1.86%||10.16%||2.18%|
Institutional & Insider Ownership
42.4% of Standard Diversified Inc Class A (NYSEAMERICAN) shares are owned by institutional investors. 10.2% of Standard Diversified Inc Class A (NYSEAMERICAN) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Standard Diversified Inc Class A (NYSEAMERICAN) beats ADOCIA/S on 7 of the 8 factors compared between the two stocks.
ADOCIA/S Company Profile
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed based on novel polymers, oligomers, and small molecules to enhance the effectiveness and/or safety of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analogs; HinsBet U100, a rapid-acting formulation of human insulin; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide; and BioChaperone Human Glucagon, an aqueous formulation of human glucagon. It is also developing BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide that are combinations of insulin glargine with GLP-1s; BioChaperone Teduglutide, an aqueous formulation of teduglutide, a GLP-2 analog for the treatment of short bowel syndrome; and BioChaperone Glucagon GLP-1, a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. Adocia SA was founded in 2005 and is headquartered in Lyon, France.
Standard Diversified Inc Class A (NYSEAMERICAN) Company Profile
Standard Diversified, Inc. operates as shell company, which intends to identify new business and investment opportunities. The company was founded by Martha C. Reider and Richard C. Birkmeyer in 1990 and is headquartered in Mineola, NY.
Receive News & Ratings for ADOCIA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADOCIA/S and related companies with MarketBeat.com's FREE daily email newsletter.